109 related articles for article (PubMed ID: 8557231)
1. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Skilling JS; Squatrito RC; Connor JP; Niemann T; Buller RE
Gynecol Oncol; 1996 Jan; 60(1):72-80. PubMed ID: 8557231
[TBL] [Abstract][Full Text] [Related]
2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
3. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
4. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines.
Yaginuma Y; Westphal H
Cancer Res; 1992 Aug; 52(15):4196-9. PubMed ID: 1638534
[TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of human ovarian carcinoma cell lines.
Yuan Y; Kim WH; Han HS; Lee JH; Park HS; Chung JK; Kang SB; Park JG
Gynecol Oncol; 1997 Sep; 66(3):378-87. PubMed ID: 9299249
[TBL] [Abstract][Full Text] [Related]
6. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
[TBL] [Abstract][Full Text] [Related]
7. An abundance of p53 null mutations in ovarian carcinoma.
Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
[TBL] [Abstract][Full Text] [Related]
8. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
9. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
10. p53 expression, mutation, and allelic deletion in ovarian cancer.
McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
[TBL] [Abstract][Full Text] [Related]
11. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
12. Absence of p51 alteration in human ovarian cancer.
Shinozaki H; Okamoto A; Shimizu K; Saito M; Yokota J; Ochiai K
Int J Oncol; 2001 Mar; 18(3):549-52. PubMed ID: 11179485
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
[TBL] [Abstract][Full Text] [Related]
14. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.
Elbendary AA; Cirisano FD; Evans AC; Davis PL; Iglehart JD; Marks JR; Berchuck A
Clin Cancer Res; 1996 Sep; 2(9):1571-5. PubMed ID: 9816335
[TBL] [Abstract][Full Text] [Related]
15. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
16. Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines.
Janicek MF; Sevin BU; Nguyen HN; Averette HE
Gynecol Oncol; 1995 Oct; 59(1):87-92. PubMed ID: 7557622
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of p53 gene in gynecologic tumors].
Yaginuma Y; Yamashita T; Duenas JC; Katayama H; Ishikawa M
Rinsho Byori; 1994 Mar; 42(3):235-41. PubMed ID: 8152158
[TBL] [Abstract][Full Text] [Related]
18. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.
Collinet P; Vereecque R; Sabban F; Vinatier D; Leblanc E; Narducci F; Querleu D; Quesnel B
J Obstet Gynaecol Res; 2006 Oct; 32(5):449-53. PubMed ID: 16984510
[TBL] [Abstract][Full Text] [Related]
19. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog.
Van Leeuwen IS; Hellmèn E; Cornelisse CJ; Van den Burgh B; Rutteman GR
Anticancer Res; 1996; 16(6B):3737-44. PubMed ID: 9042250
[TBL] [Abstract][Full Text] [Related]
20. [Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer].
Guan X; Lang J; Bian M
Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):165-7. PubMed ID: 10682487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
